Status:

RECRUITING

National PROspective Infrastructure for Renal Cell Carcinoma (PRO-RCC)

Lead Sponsor:

PROspective Renal Cancer Cohort Foundation

Collaborating Sponsors:

Comprehensive Cancer Centre The Netherlands

Merck Sharp & Dohme LLC

Conditions:

Renal Cancer

Renal Cell Carcinoma

Eligibility:

All Genders

18+ years

Brief Summary

PRO-RCC is a nationwide long-term cohort for the collection of real-world clinical data, patient reported outcome measures (PROMs) and patient reported experience measures (PREMs) that provides an inf...

Detailed Description

PRO-RCC is designed as a multicenter cohort for all Dutch patients with localized RCC or metastatic renal cell carcinoma (mRCC). The clinical data collection is embedded in the framework of the Nether...

Eligibility Criteria

Inclusion

  • newly diagnosed patients with RCC or synchronous metastatic RCC
  • metachronous metastasized RCC
  • age \>18 years
  • capable of understanding Dutch language

Exclusion

  • n/a

Key Trial Info

Start Date :

January 19 2023

Trial Type :

OBSERVATIONAL

Allocation :

ESTIMATED

End Date :

January 1 2030

Estimated Enrollment :

2000 Patients enrolled

Trial Details

Trial ID

NCT05326620

Start Date

January 19 2023

End Date

January 1 2030

Last Update

June 6 2025

Active Locations (27)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 7 (27 locations)

1

Amsterdam UMC locatie VUMC

Amsterdam, North Holland, Netherlands

2

Jeroen Bosch Ziekenhuis

's-Hertogenbosch, Netherlands

3

Jeroen Bosch Ziekenhuis

's-Hertogenbosch, Netherlands

4

Meander Medisch Centrum

Amersfoort, Netherlands